A phase 1, open-label, dose-escalation study to
evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer, NCT01969643
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. Increasing doses of SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab.
MORE DETAILS ON THIS TRIAL
16104 / NCT01969643 / Open 2-10-2017